NeuroSearch A/S

NEUR 
(NasdaqOMXC) 
 

To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.

dkk 3.54 <%= Resources.Global.txtDown %>
Updated 23/06/2017
Change % -0.28% Stock price decreasing
Change -0.01 Stock price decreasing
Volume 11,503
High DKK 3.54
Low DKK 3.50
Open DKK 3.50
ISIN DK0010224666
Prev close DKK 3.55
# of shares 24.55M
Market cap 86.92M DKK
Intraday

Market closed
NeuroSearch A/S
Market is closed, opens at 08:00
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  3.54 -0.3% Stock price decreasing -0.6% Stock price decreasing -5.1% Stock price decreasing 23.3% Stock price increasing 32.1% Stock price increasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2016
0
-6,300
22,815
71,383
79,421
2015
0
-6,488
-5,538
72,400
78,594
2014
0
-13
-8
78
84
2013
29
-10
12
88
92
2012
121
-290
-276
81
208
2011
0
-383
-678
321
841
2010
69
-328
-259
994
1,392
2009
85
-356
-287
1,174
0
2008
67
-366
-382
0
0
2007
115
-253
-268
1,121
0
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Orexigen Therapeutics Inc 3.12 11.8% Stock price increasing 8.7% Stock price increasing -21.6% Stock price decreasing 72.4% Stock price increasing 595.2% Stock price increasing 79.3% Stock price increasing
 
Vivus Inc 1.22 6.1% Stock price increasing 10.9% Stock price increasing 10.9% Stock price increasing -3.2% Stock price decreasing 10.9% Stock price increasing 6.1% Stock price increasing
 
Arena Pharmaceuticals Inc 14.88 1035.9% Stock price increasing 978.3% Stock price increasing 919.2% Stock price increasing 872.5% Stock price increasing 722.1% Stock price increasing 947.9% Stock price increasing
 
H Lundbeck A/S 373.20 2.3% Stock price increasing 6.7% Stock price increasing 17.2% Stock price increasing 34.5% Stock price increasing 57.8% Stock price increasing 29.9% Stock price increasing

Company profile

NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.

Peers

Instruments Last Change  
Orexigen The.. 3.12 1.0% Stock price increasing
82,100,86,30,43,44,69,69,86,95
Vivus Inc 1.22 5.2% Stock price increasing
25,0,6,6,12,6,18,18,18,100
Arena Pharma.. 14.88 -8.1% Stock price decreasing
100,42,26,25,35,41,17,15,1,17
Lundbeck A/S 373.20 -3.3% Stock price decreasing
6,32,19,35,32,55,51,61,52,60

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2017 06:22:36
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170623.1 - EUROWEB4 - 2017-06-24 07:22:36 - 2017-06-24 06:22:36 - 1000 - Website: OKAY